Biopharmaceutical company ImaRx Therapeutics of Tucson, AZ, reported revenue gains for the second quarter of 2007 (end June-30).
Revenue for the period was $2.2 million, up from $300,000 in 2006. Revenue for the six-month period was $3.4 million, compared to $400,000 the previous year.
ImaRx attributed its healthy earnings to the launch of Abbokinase, its therapy for the treatment of acute massive pulmonary embolism, which accounted for $2 million of its revenue in the second quarter.
On another positive note, the company's net loss for the period was $1.5 million, compared to $4.1 million in the second quarter of 2006.
By AuntMinnie.com staff writers
August 31, 2007
Related Reading
ImaRx wins NIH study grant, August 23, 2007
ImaRx prices IPO, shares edge lower, July 27, 2007
Bracco, ImaRx sign licensing pact, July 4, 2007
ImaRx files S-1 for IPO, May 5, 2007
Unger steps down at ImaRx, October 24, 2006
Copyright © 2007 AuntMinnie.com
